readthroughSign in
CompanySPRONasdaqCambridge, MA

Spero Therapeutics, Inc.

Spero Therapeutics is a clinical-stage biopharmaceutical company developing SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody for IgG4-related disease and other immune-mediated conditions.

8-KNov 12Latest SEC filing
Nov 12Latest story